SCHEMBL460175

SCHEMBL460175

O=S(=O)(O)c1c(-c2ccccc2)cccc1S(=O)(=O)OO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.38
HDAC4 P56524 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
BCAT2 O15382 1/20 0.36
DAPK1 P53355 1/20 0.36
CASP1 P29466 2/20 0.35
PTGS2 P35354 1/20 0.35
CYP2D6 P10635 1/20 0.35
TTR P02766 1/20 0.35
FABP4 P15090 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
MAPK14 Q16539 1/20 0.35
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NR4A1 P22736 1/20 0.34
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30166530 0.86 TSHR (0.41) HNF4AHDAC4HDAC2HDAC8HDAC6
SCHEMBL392931 0.86 TSHR (0.41) HNF4AHDAC4HDAC2HDAC8HDAC6
Hydrochloric Acid SCHEMBL11760140 0.84 PTGS2 (0.40) HNF4AHDAC4HDAC2HDAC8HDAC6
SCHEMBL21794264 0.80 TSHR (0.46) HNF4AHDAC4HDAC2HDAC8HDAC6
SCHEMBL27690669 0.80 STAT3 (0.44) BCAT2PTGS2CDK2ALDH1A1HPGD
Urea SCHEMBL4970936 0.80 BCAT2 (0.46) HNF4ABCAT2DAPK1CASP1PTGS2
SCHEMBL2731656 0.80 CASP1 (0.37) HNF4AHDAC4HDAC2HDAC8HDAC6
Ether SCHEMBL2731657 0.78 PTGS2 (0.37) CASP1PTGS2TTRFABP4CCNA2
Phthalic Acid SCHEMBL8745684 0.77 HNF4A (0.53) HNF4ABCAT2CYP2D6FABP4TSHR
(Z)-1,2-Diphenylethene SCHEMBL28265888 0.77 PTPN1 (0.44) HDAC4HDAC2HDAC8HDAC6CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060193789-A1 Surfacant, film forming agent, water, gas propellant; plant and animal extracts and oils; may include malathion FOAMIX LTD. (IL) 2006-08-31 US claimed
US-20240099948-A1 Compositions Comprising Silicon Dioxide-Based Particles Including One or More Agents COLABS INT'L CORP. (US) 2024-03-28 US disclosed
US-11839674-B2 Compositions comprising silicon dioxide-based particles including one or more agents CoLabs International Corporation (US) 2023-12-12 US disclosed
US-11752086-B2 Topical formulations and methods MYOCEPT INC. (US) 2023-09-12 US disclosed
US-11724134-B2 Compositions containing a cellulose derived capsule with a sunscreen active agent CoLabs International Corporation (US) 2023-08-15 US disclosed
EP-3813786-A1 COMPOSITIONS COMPRISING SILICON DIOXIDE-BASED PARTICLES INCLUDING ONE OR MORE AGENTS Colabs International Corporation (US) 2021-05-05 EP disclosed
US-10889753-B2 Self-breakable treatment fluids for use in subterranean formation operations HALLIBURTON ENERGY SERVICES, INC. (US) 2021-01-12 US disclosed
US-20190290940-A1 Compositions Containing a Cellulose Derived Capsule with a Sunscreen Active Agent CoLabs International Corporation (US) 2019-09-26 US disclosed
US-10322301-B2 Compositions containing a cellulose derived capsule with a sunscreen active agent CoLabs International Corporation (US) 2019-06-18 US disclosed
US-20190127629-A1 SELF-BREAKABLE TREATMENT FLUIDS FOR USE IN SUBTERRANEAN FORMATION OPERATIONS HALLIBURTON ENERGY SERVICES, INC. 2019-05-02 US disclosed
US-20060093636-A1 Comprises allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water; composition is in the form of an oil-in-water emulsion; pH of the composition is about 3.0 to 6.0; preferred acidic anionic polymer is a carboxypolymethylene polymer; stability ALWYN COMPANY, INC. (US) 2006-05-04 US disclosed
US-20060067959-A1 Compositions and methods for treatment of solar damage NIMNI MARCEL 2006-03-30 US disclosed
US-20060045926-A1 Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin NIMNI MARCEL 2006-03-02 US disclosed
WO-2003070161-A2 EMULSIFIED SKIN CARE COMPOSITION CONTAINING SALICYLIC ACID, LANOLIN OIL, AND PROPYLENE GLYCOL ALWYN COMPANY, INC. (US) 2003-08-28 WO disclosed
US-20030157137-A1 Emulsified skin care composition containing salicylic acid, lanolin oil, and propylene glycol ALWYN COMPANY, INC. 2003-08-21 US disclosed
US-20030147968-A1 Allantoin-containing preparations for administration as gels and aerosols ALWYN COMPANY, INC. 2003-08-07 US disclosed
WO-2003053369-A1 ALLANTOIN-CONTAINING PREPARATIONS FOR ADMINISTRATION AS GELS AND AEROSOLS ALWYN COMPANY, INC. (US) 2003-07-03 WO disclosed
US-20020054895-A1 And at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water; skin protectants ALWYN COMPANY, INC. 2002-05-09 US disclosed
US-6376557-B1 TRANSDERMAL SUPPLYING ZAVERI CHANDA BHUWALKA (US) 2002-04-23 US disclosed
WO-2001068107-A1 HAIR RESTORATION FORMULATION ZAVERI CHANDA BHUWALKA (US) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11724134-B2 Compositions containing a cellulose derived capsule with a sunscreen active agent CUTA, ACMSD, TYR HNF4A 4375/4885HDAC4 561/4885HDAC2 1500/4885
US-20060045926-A1 Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin COL1A1, COL14A1, COL2A1 HNF4A 2102/4885HDAC4 3666/4885HDAC2 4336/4885
US-20190290940-A1 Compositions Containing a Cellulose Derived Capsule with a Sunscreen Active Agent CUTA, ACMSD, TYR HNF4A 4375/4885HDAC4 561/4885HDAC2 1500/4885
US-11752086-B2 Topical formulations and methods KRT18, ANXA3, VIP HNF4A 2498/4885HDAC4 2254/4885HDAC2 4372/4885
US-10322301-B2 Compositions containing a cellulose derived capsule with a sunscreen active agent CUTA, ACMSD, TYR HNF4A 4375/4885HDAC4 561/4885HDAC2 1500/4885
US-20240099948-A1 Compositions Comprising Silicon Dioxide-Based Particles Including One or More Agents MSN, LIPE, CUTA HNF4A 4473/4885HDAC4 1891/4885HDAC2 3227/4885
US-11839674-B2 Compositions comprising silicon dioxide-based particles including one or more agents MSN, LIPE, CUTA HNF4A 4489/4885HDAC4 1967/4885HDAC2 3302/4885
US-20060067959-A1 Compositions and methods for treatment of solar damage AAAS, LRRK2, CSTB HNF4A 4606/4885HDAC4 4506/4885HDAC2 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.